KFF analysis has found that 10 drugs account for 22% of all Medicare Part D spending in 2021.
Formulary Watch
Latest News
All News
Advertisement
Prime Therapeutics’ analysis of claims data suggests patients require support to ensure continued use and lifestyle modification.
Opill will be available in stores and online in the first quarter of 2024.
A 30-day supply of Brenzavvy is available from Cost Plus Drugs for $47.85.
Beginning in January 2024, if GoodRx shows a lower CVS price than a member’s plan price, that lower price will automatically be given.
About half of Navitus’ commercial clients saw a drug spend decrease compared with 2021.
Takeda indicated that it could not address issues related to aspects of data collection within the current BLA review cycle.
Governor Phil Murphy has signed three pieces of legislation that would require PBMs to use prescription drug rebates to lower premiums and out-of-pocket costs for consumers and prevent the practice of spread pricing.
The label for Leqvio has also been updated to remove four adverse events based on recent safety data.
Express Scripts will also add Sandoz’s unbranded version of adalimumab to its National Preferred Formulary. The Humira biosimilar Amjevita was added previously.
Advertisement
Medicare will cover Alzheimer’s drugs with full approval, including Leqembi — if the physician and patient participate in a real-world registry trial to gather additional data.
There is a risk the inhaler wouldn’t provide the right dose.
RxPreferred will offer Yusimry, a biosimilar of Humira, at a price of $569.27 plus dispensing and shipping fees. This price represents a 92% discount off Humira’s monthly price.
Zolbetuximab is a first-in-class therapy for advanced gastric and gastroesophageal cancers. The target action date is Jan. 12, 2024.
The Magellan Rx Management CEO is replacing Ken Paulus, who has held the top job at Prime since May 2019.
The FDA is asking for more pharmacokinetic data on carbidopa, one of the drugs within IPX203. The therapy is an extended-release, oral formulation of carbidopa/levodopa.
Most of the Humira biosimilars are available with two pricing options. Of the larger PBMs, only Optum Rx so far has weighed in on a coverage decision.
Similar to Amgen’s Amjevita, Hulio will be offered at a list price of 5% below and 85% below the current Humira list price.
The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
How the insurance industry denies claims; consumers confused by complexity and red tape; and how the ALS drug Relyvrio came to be.
Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
A carton of Hadlima including two pre-filled pens or two pre-filled syringes is available at a list price of $1,038.
In the revised guidance, CMS clarified aspects of the negotiation process and outlined additional opportunities for engagement during the process. CMS will publish by Sept. 1, 2023, the list of the first 10 drugs for price negotiation.
Biosimilars have the potential to lower costs, but the adoption has been slower than expected, a recent study finds.
BioMarin is offering an outcomes-based warranty that will reimburse payers up to 100% of the cost if a patient does not respond to Roctavian.
Longer-acting growth hormone reduces frequency of injections. It will be available in August.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
Midlife influenza vaccine not associated with increased risk of Parkinson’s disease, study shows
5
